small-logo
ProfessionalsCapabilitiesInsights & NewsCareersLocations
About UsAlumniOpportunity & InclusionPro BonoCorporate Social Responsibility
Stay Connected:
facebookinstagramlinkedintwitteryoutube
Site Search

Capabilities 78 results

Practice Area

Product Liability & Mass Torts

Major multinational companies trust Winston to defend their products and reputations in high-profile, high-stakes product liability and mass tort claims. Our Product Liability & Mass Torts Practice is one of the industry’s most seasoned, with a deep bench of experienced lawyers and a unique combination of extensive trial experience and expansive technical knowledge....Read more

Practice Area

Derivatives & Structured Products

Winston represents swap dealers, major swap participants, financial intermediaries, hedge funds, national exchanges, and end-users in a broad array of derivative transactions ranging from highly structured transactions to more traditional trading or hedging transactions, and in regulatory and enforcement issues related to commodities and derivatives....Read more

Industry

Medical Devices

The medical device industry is currently undergoing monumental change—from supply chain challenges to disruptive technologies and economic fluctuations. To pave the way for a more accessible and innovative healthcare landscape—including advances in wearables, implants, diagnostics, mobility, drug delivery—the evolving and expansive medical device industry faces wide-ranging legal needs. Clients in this sector can tap the remarkable depth and breadth of our sector-focused and skilled attorneys in the U.S. and abroad. Our Healthcare & Life Sciences Industry Group engages clients at all points in the product development life cycle to provide sound advice and practical solutions regardless of the client’s size or the complexity of their need. We help clients navigate today’s complex regulatory landscape, defend products and reputations in the face of high-profile product liability and mass tort claims, protect innovative intellectual property (IP), and leverage cross-border experience to advise on commercial transactions....Read more

Experience 129 results

Experience

|

November 26, 2025

Winston & Strawn Represented CFS Brands in its Acquisition of Cornerstone Foodservice Group

Winston represented CFS Brands, a portfolio company of TJC, in its acquisition of Cornerstone Foodservice Group, a global leader in foodservice equipment serving both front- and back-of-house applications through a portfolio of established, innovative brands. ...Read more

Experience

|

August 19, 2025

Winston Advised Ellipsis Onshore Holdings in the Acquisition of Oil and Gas Non-Operated Assets in the Permian Basin of Texas and New Mexico

Winston advised Ellipsis U.S. Onshore Holdings LLC, a portfolio company of the Westlawn Group, in connection with the acquisition of high-quality, non-operated working interests in the Permian Basin of Texas and New Mexico—adding approximately 4,000 barrels of oil equivalent per day in net production and over 600 gross remaining drilling locations. This strategic transaction strengthens Ellipsis’ Delaware Basin footprint and supports its strategy of scaling through high-margin, low-cost assets....Read more

Experience

|

July 24, 2025

Linkhome Holdings Inc. IPO

Winston & Strawn LLP represented Linkhome Holdings Inc., a leading AI-powered U.S. real estate platform, in connection with its upsized $6 million initial public offering. The offering consisted of 1,500,000 shares of common stock priced at $4.00 per share, and the shares are expected to begin trading on the Nasdaq Capital Market under the ticker “LHAI” on July 24, 2025....Read more
View All Experience

Insights & News 2,163 results

Article

|

January 6, 2026

|

5 Min Read

Guardrails Before Greenlights: How Gen AI Will Actually Shape E-discovery in 2026

This article was originally published in LegalTech News. Any opinions in this article are not those of Winston & Strawn or its clients. The opinions in this article are the authors’ opinions only....Read more

Client Alert

|

December 31, 2025

|

4 Min Read

New York FAIR Business Practices Act Bolsters State’s Consumer Protection Framework

Not quite a year after the Consumer Financial Protection Bureau (CFPB) issued its January 2025 report urging states to strengthen state-level consumer protections, New York enacted the Fostering Affordability and Integrity through Reasonable (FAIR) Business Practices Act into law. The FAIR Act amends New York’s general business law to prohibit unfair and abusive business acts and practices beyond deceptive conduct.

Competition Corner

|

December 23, 2025

|

4 Min Read

The Continuing Expansion of Algorithmic Software Laws – Best Practices for Companies in an Evolving Landscape

New York recently expanded its algorithmic pricing laws, now requiring retailers to disclose when prices are set with algorithmic software based on consumers’ personal data.The so-called practice of surveillance pricing entails adjusting prices charged for goods and services according to monitored personal data.

View All Insights & News

Other Results 86 results

Law Glossary

What Are Interchangeable Biological Products?

A biological product is interchangeable if it is biosimilar to the reference product and is expected to produce the same clinical result as the reference product in any given patient. A biosimilar product that is deemed to be interchangeable by the FDA means the biosimilar product can be substituted for the reference product by a pharmacist without consulting the prescriber. The specific requirements for substitution vary by state....Read more

Site Content

What Is General Causation?

In the product liability context, general causation is the legal and scientific determination of whether the product in question has the inherent capability to cause the alleged injury under certain circumstances. Establishment of general causation is a critical aspect of a plaintiff’s case, and typically requires scientific evidence, such as epidemiology or toxicology, and expert testimony to establish a causal connection between the product’s design, manufacturing, or warnings and the injury or injuries at issue. As contrasted to specific causation, the focus in a general causation inquiry is on whether the product or exposure, as a general matter, can cause the type of injury claimed by the plaintiff. A general causation inquiry does not assess any facts unique to a particular plaintiff....Read more

Site Content

What Is a Biosimilar?

A subset of biologics, a biosimilar is a biologic that is highly similar to an FDA-approved product, referred to as the reference product. Biosimilars have no clinically meaningful differences compared to a reference product in terms of safety, purity, and potency as demonstrated through human pharmacokinetic and pharmacodynamics studies. Because of their complexity, biosimilars are unlikely to be identical replicates of their comparable reference products....Read more
Logo
facebookinstagramlinkedintwitteryoutube

Copyright © 2026. Winston & Strawn LLP

AlumniCorporate Transparency Act Task ForceDEI Compliance Task ForceEqual Rights AmendmentLaw GlossaryThe Oval UpdateWinston MinutePrivacy PolicyCookie PolicyFraud & Scam AlertsNoticesSubscribeAttorney Advertising